Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | PLAU | P00749 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4842166 | 0.78 | CXCR5 (0.41) | MEN1KMT2AALDH1A1POLBHTT | |
| SCHEMBL2211499 | 0.77 | ALDH1A1 (0.41) | MEN1KMT2AALDH1A1POLBHTT | |
| SCHEMBL2210519 | 0.75 | POLB (0.43) | MEN1KMT2AALDH1A1POLBHTT | |
| SCHEMBL2208021 | 0.74 | KMT2A (0.44) | MEN1KMT2AALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL2209056 | 0.71 | POLB (0.39) | MEN1KMT2AALDH1A1POLBHTT | |
| SCHEMBL2205619 | 0.69 | KMT2A (0.41) | MEN1KMT2AALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL6654038 | 0.69 | KMT2A (0.47) | MEN1KMT2AALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL2209439 | 0.68 | NPSR1 (0.45) | MEN1KMT2AALDH1A1POLBHTT | |
| SCHEMBL7712031 | 0.68 | NPSR1 (0.38) | MEN1KMT2AALDH1A1POLBHTT | |
| SCHEMBL2210116 | 0.68 | KMT2A (0.43) | MEN1KMT2AALDH1A1POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7396947-B2 | Chiral ligands for application in asymmetric syntheses | LANXESS DEUTSCHLAND GMBH (DE) | 2008-07-08 | — | — | US | disclosed |
| US-20070004927-A1 | Chiral ligands for application in asymmetric syntheses | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-04 | — | — | US | disclosed |
| US-20060161022-A1 | Chiral ligands for application in asymmetric syntheses | LANXESS DEUTSCHLAND GMBH (DE) | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004927-A1 | Chiral ligands for application in asymmetric syntheses | COASY, SPR, DHPS | MEN1 1809/4885KMT2A 3704/4885ALDH1A1 348/4885 |
| US-20060161022-A1 | Chiral ligands for application in asymmetric syntheses | COASY, SPR, DHPS | MEN1 1809/4885KMT2A 3704/4885ALDH1A1 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.